# Hansoh BioMedical R&D Company: Phase 2 study in Moderate-to-severe Plaque Psoriasis (390 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Hansoh BioMedical R&D Company |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis |
| NCT ID | NCT07879885 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Moderate-to-severe Plaque Psoriasis |
| Intervention types | biological |
| Target enrollment | 390 |
| Site countries | China |
| Posted | 2026-10-19 |
| Planned start | 2025-07-31 |
| Event | Newly registered study |
| Event date | 2026-10-19 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.
- 390 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07879885). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.